C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company") 

Exercise of Options, Issue of Equity and Total Voting Rights

1 November 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces it has issued 106,425 ordinary shares of 1p each in the Company ("New Ordinary Shares") following the exercise of options by an employee of the Company.

Admission and Total Voting Rights

Application has been made for the 106,425 New Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 4 November 2022. The New Ordinary Shares will rank pari passu with the existing ordinary shares. 

Total Voting Rights

Following the issue of the New Ordinary Shares, the Company's issued share capital now consists of 252,119,597 ordinary shares. Accordingly, the figure of 252,119,597 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts

Notes to Editors:

 About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

 We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.